Roxithromycin in prevention of acute coronary syndrome associated with Chlamydia pneumoniae infection: a randomized placebo controlled trial.

@article{Leowattana2001RoxithromycinIP,
  title={Roxithromycin in prevention of acute coronary syndrome associated with Chlamydia pneumoniae infection: a randomized placebo controlled trial.},
  author={Wattana Leowattana and Kiertijai Bhuripanyo and L Singhaviranon and S. Akaniroj and Nithi Mahanonda and M Samranthin and Sasikant Pokum},
  journal={Journal of the Medical Association of Thailand = Chotmaihet thangphaet},
  year={2001},
  volume={84 Suppl 3},
  pages={S669-75}
}
The role of Chlamydia pneumoniae infection in precipitating acute coronary syndrome (ACS) is unclear. Some studies have indicated that intervention with macrolide antibiotics might reduce coronary events in patients with ACS. A double blind, randomized, placebo-control trial was conducted on 84 ACS patients. Patients were randomized to 30 days of treatment with roxithromycin (150 mg, twice daily) or matching placebo. The follow-up period was 90 days, and the primary clinical end point included… CONTINUE READING
10 Extracted Citations
0 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 10 extracted citations

Similar Papers

Loading similar papers…